Global gene therapy products market is set to witness a substantial CAGR in the forecast period of 2020- 2026.Gene therapy or human gene therapy is a process which is used to modify gene for the treatment of any disease.Plasmid DNA, bacterial vector, human gene editing technology and viral vectors are some of the most common type of gene therapy products.The main aim of the gene therapy is to replace the dysfunctional genes.Somatic and germline are some of the most common type of the gene therapy.Download exclusive PDF sample [email protected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-therapy-products-marketKey Market Competitors:Few of the major competitors currently working in the global gene therapy products market are Adaptimmune., Anchiano Therapeutics, bluebird bio, Inc., CELGENE CORPORATION,  GlaxoSmithKline plc., Merck KGaA, Novartis AG, Achieve Life Sciences, Inc., Spark Therapeutics, Inc., Abeona Therapeutics, Inc, Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics, AveXis, Inc., CRISPR Therapeutics, Intellia Therapeutics, Inc and Gilead Sciences,Inc.among others.Segmentation: Global Gene Therapy Products MarketBy Product (Yescarta, Kymriah, Luxturna, Strimvelis, Gendicine)By Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious diseases, Other Diseases)By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)Competitive Analysis: Global Gene Therapy Products MarketGlobal gene therapy products market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The global biotechnology market is estimated to reach USD 727.12 billion by 2026 growing at a CAGR of 6.84% during the forecast period, according to a new study published by Polaris Market Research.The report ‘Biotechnology Market Share, Size, Trends & Industry Analysis Report, By Technology (Fermentation, Tissue Engineering and Regeneration, PCR Technology, Nanobiotechnology, Chromatography, DNA Sequencing, Cell Based AssaysOthers); By Application (BioPharmacy, BioServices, BioAgriculture, BioIndustrial, Bioinformatics); and By Regions: Segment Forecast, 2019 – 2026’ provides an extensive analysis of present market dynamics and predicted future trends.Growing hepatitis B disease, increasing interest of horticultural items such as sugarcane, rice, beans, and wheat due from the increasing populations in economies such as U.S., China and India are expected to push the overall biotechnology market.The growth of this market is further propelled by elements such as deficiency of water, low yield of items, insect attacks, and constrained availability of agrarian land, which is promoting the companies to invest and conduct R activities at a broader scale.Another factor which is helping the market growth includes regenerative medicines.Existence of a huge section of businesses concentrating on the advancement of regenerative treatments is anticipated to push the market development through to 2026.Governments are associating with private companies for expanding their research into this domain.Owing to technological improvements and prevalent applications of biotechnology in healthcare is helping the market to gain a strong growth during the forecast period.
The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system.These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.These disorders are usually genetic and arise due to abnormal cell development at the embryo stage.Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5937The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin.Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally.Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the market growth.Global market for neurocutaneous disorders is expected to have a CAGR of approximately 6.5% during 2017 to 2023.SegmentationThe global neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.On the basis of type, the global neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis.The Sturge-weber syndrome is divided into type-1, type-2, and type-3.On the basis of diagnosis, the global neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and othersOn the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others.
Summary – A new market study, “Global Covid-19 Treatment Market Size, Status and Forecast 2020-2026” has been featured on WiseGuyReports.This report focuses on the global Covid-19 Treatment status, future forecast, growth opportunity, key market and key players.The study objectives are to present the Covid-19 Treatment development in North America, Europe, China, Japan, South Korea, Middle East, Southeast Asia and Central & South America.Also Read:  https://www.medgadget.com/2020/08/covid-19-treatment-market-2020-global-leading-companies-analysis-revenue-trends-and-forecasts-2026.htmlThe key players covered in this studyApplied DNA Sciences, IncCodagenixGeoVax Labs, Inc.Takis BiotechEvvivaxZydus CadilaMIGAL Galilee Research InstituteGenerex Biotechnology CorporationModerna TherapeuticsNovavaxBravovaxAscletis PharmaJanssen PharmaceuticalsAltimmuneGreffex Inc.CanSino Biologics, Inc.ExpreS2ion Biotechnologies ApSClover BiopharmaceuticalsVaxil Bio Ltd.iBio Pharma IncTonix PharmaceuticalsCurevacImmunoPreciseAlso Read: https://www.einpresswire.com/article/521574455/employee-engagement-app-market-2020-global-analysis-industry-growth-current-trends-and-forecast-till-2025Market segment by Type, the product can be split intoby Treatment TypeRespiratory SupportCirculatory Support.Convalescent Plasma TherapyAntiviral Medicine (a-interferon, lopinavir/ritonavir, ribavirin)Antimicrobial TherapyRenal Failure and Renal Replacement TherapyLung Replacement TherapyImmunotherapyOther therapeutic measuresby Severity DegreeLightOrdinaryHeavyCriticalConvalescenceAlso Read:  http://www.marketwatch.com/story/global-nail-care-market-2020-key-players-sales-consumption-demand-growth-segmentation-and-forecast---2026-2020-11-24Respiratory support including oxygen therapy, high-flow nasal catheter oxygen therapy or non-invasive mechanical ventilation, invasive mechanical ventilation, extracorporeal membrane pneumonectomy (ECMO).Circulatory support refers to use vasoactive drug on the base of full fluid resuscitation and improved microcirculation.For else, antiviral medicine includs a-interferon, lopinavir/ritonavir, ribavirin, etc.Also Read:  http://www.marketwatch.com/story/global-healthcare-analytical-testing-services-market-2021-analysis-opportunities-and-forecast-to-2027-2021-01-08Market segment by Application, split intoChildrenAdultSpecial GroupsSpecial groups refers to pregnants and others.Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSouth KoreaMiddle EastSoutheast AsiaCentral & South America The study objectives of this report are:To analyze global Covid-19 Treatment status, future forecast, growth opportunity, key market and key players.To present the Covid-19 Treatment development in North America, Europe, China, Japan, South Korea, Middle East, Southeast Asia and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.Also Read:  https://www.marketwatch.com/press-release/cloud-based-managed-services-market-market-growth-opportunities-2021-2027-business-investment-with-leading-companies-2020-12-30?tesla=yIn this study, the years considered to estimate the market size of Covid-19 Treatment are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year.Whenever data information was unavailable for the base year, the prior year has been considered.
The robo-vessel will map the ocean floor, and its solar-powered sensors will sample fish DNA and collect climate data.
2
This study involved the extensive use of both primary and secondary sources.The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.Major Growth Drivers:The growth of this market is primarily attributed to factors such as the increasing demand for synthetic genes & synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing & synthesizing, increasing R funding & initiatives in synthetic biology, and increasing investments in the market.Expected Revenue Growth:The synthetic biology market is projected to reach USD 19.8 billion by 2025 from USD 6.8 billion in 2020, at a CAGR of 23.9%.Accessories to Fuel the Growth of Synthetic Biology Market :The research being conducted in the field of pharmaceuticals, synthetic vaccines, fuel alternatives, textile industry, and green chemicals is expected to propel market growth in the coming years.Growing initiatives in this field along with the rising R funding activities with the increasing potential of synthetic biology is increasing the adoption of various tools and technologies.The declining cost of DNA sequencing and synthesizing is improving their adoption which is aiding players to cater to a larger end user base and improve their market share.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889By tool, oligonucleotides and synthetic DNA dominated the synthetic biology market in 2019.Based on tools, the market segmented into oligonucleotides and synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms and xeno-nucleic acid.In 2019, the oligonucleotides and synthetic DNA segment accounted for the largest share of the market, followed by enzymes.The large share of the segment can be attributed to the rising demand for synthetic DNA, synthetic RNA, and synthetic genes, which are used in a wide range of research applications.Gene synthesis accounted for the largest share of the synthetic biology market in 2019.Based on technology, the market is segmented into gene synthesis, genome engineering, cloning, sequencing, site-directed mutagenesis, measurement & modeling, microfluidics, nanotechnology, and bioinformatics technologies.
1
New York, NY 18 Jan 2021: According to a new study published by Polaris Market Research, the global Next Generation Sequencing (NGS) market is anticipated to reach USD 16.6 billion by 2025.Using next generation sequencer, the process produces a million DNA molecules and RNA sequences by allowing rapid nucleotide sequencing.An entire human genome can be sequenced in a single day using next generation sequencing, however, the Sanger sequencing technology, used to decode the human genome, required over a decade to bring the final summary.By providing high flexibility, speed, throughput, and reduced sequencing cost, the introduction of next generation sequencing technologies has brought significant changes in sequencing technologies.By application, the global next generation sequencing market is categorized as, drug discovery/personalized medicine, genetic screening, diagnostics/infectious diseases, agricultural & animal research, and others.The increasing demand of next generation sequencing base test for infectious diseases and cancer, and rising focus on developing and providing next generation sequencing- based diagnostic tests are the major factors contributing towards the high market share of the segment in the global market.
Enzymes help accelerate chemical reactions in the human body.They are necessary for breathing, digesting food, running muscles and nerves, but also in thousands of other roles.The basicsEnzymes are made of proteins folded into complex shapes.Once the products leave the active area, the enzyme is ready to cling to a new substrate and repeat the process.What do enzymes do?In the digestive system – Enzymes help the body break down larger complex molecules into smaller molecules, such as glucose, so that the body can use them as fuel.DNA copying – Every cell in your body contains DNA.To do this, a number of enzymes are used.How do enzymes work?The "lock and key" model was first proposed in 1894.Most enzymes in the human body work best at about 37° C – body temperature.At lower temperatures, they will still work but much slower.
7
Summary – A new market study, “Global Covid-19 Vaccine Market Size, Status and Forecast 2020-2026”has been featured on WiseGuyReports.This report focuses on the global Covid-19 Vaccine status, future forecast, growth opportunity, key market and key players.The study objectives are to present the Covid-19 Vaccine development in North America, Europe, China, Japan, South Korea, Middle East, Southeast Asia and Central & South America.The key players covered in this study Inovio Pharmaceuticals Takis Biotech (Evvivax) Zydus Cadila Codagenix, Inc. GeoVax, Inc. Bravovax Janssen Pharmaceutical Companies Altimmune Vaxart CanSino BiologicsAlso Read: https://www.einpresswire.com/article/526518170/global-covid-19-vaccine-market-analysis-2020-dynamics-trends-revenue-segmented-outlook-forecast-till-2026ExpreS2ion Biotechnologies ApS Clover Biopharmaceuticals GSK Vaxil Bio Ltd. Generex Novavax, Inc. Sanofi Pasteur Baylor iBio, Inc. Zydus Cadila Moderna, Inc. Curevac ImmunoPrecise Also Read: https://www.einnews.com/pr_news/529342664/performance-apparel-market-global-industry-analysis-by-size-share-growth-trends-and-forecast-2020-2026 Market segment by Type, the product can be split into DNA Live Attenuated Virus NonReplicating Viral Vecto Protein Subunit RNA Market segment by Application, split into Treatment PreventionMarket segment by Regions/Countries, this report covers North America Europe China Japan South Korea Middle East Southeast Asia Central & South America Also Read: https://www.marketwatch.com/press-release/fruit-concentrate-market-report-2021-by-supply-demand-consumption-sale-price-share-revenue-and-top-manufacturers-2020-12-29?tesla=y The study objectives of this report are: To analyze global Covid-19 Vaccine status, future forecast, growth opportunity, key market and key players.To present the Covid-19 Vaccine development in North America, Europe, China, Japan, South Korea, Middle East, Southeast Asia and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.Also Read: https://www.marketwatch.com/press-release/ready-to-use-curry-market-2020-with-top-countries-data-industry-trends-share-size-top-key-players-analysis-and-forecast-research-2020-11-30?tesla=y In this study, the years considered to estimate the market size of Covid-19 Vaccine are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year.
However, recent study found it may also be efficient in aging-related disease, such as liver fibrosis.On June 17, 2020, the research team of Memorial Sloan Kettering Cancer Center announced that chimeric antigen receptor T (CAR-T) cell therapy can be used to treat diseases caused by aging, such as liver fibrosis.Compared with traditional methods such as radiation and chemotherapy, immunotherapy is more specific with less toxicity.When these CAR-T cells with recognition function are re-injected into the patient's body, they can recognize and attack cancer cells in the human body, thereby achieving the effect of killing cancer.“Currently, there are two FDA-approved CAR-T cell therapies, Novartis’ Kymriah for the treatment of acute lymphoblastic leukemia and Gilead’s Yescarta for the treatment of large B-cell lymphoma.” as introduced by a scientist from Creative Biolabs, a biotech company focusing on CAR-T therapy development services.And now, CAR-T technology also shows its glamour in diseases caused by aging.On the one hand, it can prevent the replication of cells containing damaged DNA and play an important anti-tumor function.Finding a safe way to clear senescent cells will be a major breakthrough in the treatment of these diseases.Based on these characteristics, researchers at Memorial Sloan Kettering Cancer Center began their research on cellular aging.They compared the molecules on the surface of senescent cells and other types of cells and found that a molecule called urokinase plasminogen activator receptor (uPAR) is widely present on the surface of senescent cells, but rarely appears on the surface of other cells.
The Synthetic Biology Platforms Market research report delivers a thorough analysis of this business sphere with expert insights on the past and present growth matrix.Factors such as driving forces, opportunities, and obstacles that will shape the industry dynamics are explained in detail.Besides, the study meticulously defines the size and shares of the market and its segments, uncovering the key growth prospects in the process.Global Synthetic Biology Platforms Market is expected to rise from its initial estimated value of USD 4.35 billion to an estimated value of USD 18.84 billion by 2026, registering a CAGR of 20.01% in the forecast period of 2019-2026.The report will additionally cover key agreements, associations, and global partnerships soon to change the dynamics of the market on a global scale.Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-synthetic-biology-platforms-marketMajor highlights from the Covid-19 impact analysis:Footprint of the Covid-19 pandemic on the global economy.Fluctuations in the supply & demand.Predicted outlook of the pandemic on business expansion.The market research report provides thorough insights that are enhancing the growth of the global Synthetic Biology Platforms Market, along with this, the report also provides the available opportunities and current trends that are influencing the growth of the Synthetic Biology Platforms Market and are widely used by the manufacturers.Moreover, the market research report study provides the information on current market development, its drivers, restrains and changing technologies and investment structure of the global Synthetic Biology Platforms Market.
This has got to be the Who Me? story of all time... An "error" in a "standard housekeeping process" on the UK’s controversial Police National Computer (PNC) database has led to the deletion of more than 150,000 DNA, fingerprint and other records, the Home Office has confirmed.…
5
According to the new market research report “Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instruments), Technique (Flow Cytometry, NGS, PCR, Mass Spectrometry, Microscopy), Application (Research, Medical Application), End User – Global Forecasts to 2025” published by MarketsandMarkets™.The Single-cell Analysis Market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast periodRecent Developments in Industry:In November 2019, QIAGEN launched QIAseq Multimodal Panels, which have been developed for consolidated targeted DNA and RNA enrichment and analyses.These panels save time and conserve samples that are of limited availability.In July 2019, QIAGEN partnered with Illumina with the aim to broaden the availability and use of NGS-based in vitro diagnostic (IVD) kits.In June 2019, Beckman Coulter acquired Cytobank, Inc. (US) to integrate Cytobank’s software into Beckman Coulter’s product portfolio to provide innovative solutions to customers.Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254Prominent players in this market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).These players adopted the strategies of partnerships, agreements, and acquisitions to expand their presence in the global single-cell analysis market.Becton, Dickinson and Company held the leading position in the global single-cell analysis market in 2018.The company adopts the strategies of product launches and collaborations in order to offer innovative solutions and sustain its leading position in the market.It also focuses on offering solutions and technologies to the research community in order to assist scientists and researchers by developing and manufacturing high-quality diagnostic and imaging products.Danaher Corporation held the second position in the global single-cell analysis market in 2018.The company offers a broad range of products in the single-cell analysis market, including flow cytometers, cell counters, mass spectrometers, reagents, and kits.
1
Numerous factors are adding to the aptamers market growth.Such factors, as revealed by the latest MRFR report, include increasing use in disease treatment and drug discovery, an increasing number of companies investing in the market, improvement in apatamers development technologies, and proven high diagnostic and therapeutic value of RNA aptamers with current FDA approval for the first-ever aptamers drug.The aptamers market size is likely to grow at a 20.2% CAGR between 2018- 2023 reveals the new Market Research Future (MRFR) report.Aptamers, simply put, are peptide molecules or oligonucleotides which bind to target lipid, proteins, or nucleic acid molecules.Scope of the ReportThe report categorizes the aptamers market based on type, application, technology, end-users, regions, and key players.Aptamers are single-stranded, short RNA, or DNA molecules that can bind selectively to specific targets such as live cells, toxins, carbohydrates, small molecules, proteins, and molecules.Such molecules are highly versatile and used for binding targets with high selectivity and specificity.On the contrary, strict regulations in the usage of aptamers, slow in reaching the marketplace due to regulatory hurdles, and ethical issues to use aptamers are factors that may limit the aptamers market growth over the forecast period.Key PlayersNotable players profiled in the global aptamers market report include Noxxon Pharma, Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., Neoventures Biotechnology Inc., Aptus Biotech S.L., Aptamer Solutions Ltd., Am Biotechnologies, LLC, Ophthotech Corporation, Base Pair Biotechnologies, Inc., Aptagen, LLC, and Sciences, Inc. 
At the same time, hemp seeds are grown without any pesticides, fungicides, and herbicides, which make them eco-friendly.Hemp protein also lowers the risk of diabetes, heart diseases, diverticular disease, and constipation.: https://menafn.com/1099417746/Hemp-Protein-Global-Market-Is-Expected-To-Grow-With-A-CAGR-Of-135-In-Forecast-Period-2018-2026 The global hemp protein market was valued at approximately US$ 518 million in the year 2018 and is expected reach US$ 1310.3 million by the year 2026, growing at a CAGR of approximately 12.3%.However, allergies caused due to excess use of hemp proteins and availability of substitutes: soy protein and whey proteins is restraining the growth for the market.One of them is, Its DNA structure is closely aligned with human DNA and hence, as a food source, it nourishes the body in a perfect proportion.Hemp is naturally gluten free, non GMO, free of trypsin inhibitors, and virtually free of any form of residual chemicals.In addition minimally processed and chemical-free consumption patterns has also opened an oppprtunity for the market.
A paternity DNA test is used to identify the genetic relationship between a child and the alleged father. Paternity can be either doubtful or sometimes disputed. If you are only concerned about getting a paternity DNA test for your own assurance, you can get a ‘Peace of mind DNA test’. But things may get a little complicated in case of disputes and legal matters. Let us first understand what is the basis for a paternity test and find the answers along the way. A DNA (Deoxyribonucleic acid) contains billions of nitrogen base pairs.
A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays.Currently, liquid biopsy plays a critical role in accelerating and implementing accurate oncology in clinical settings by leading to an improved understanding of tumour heterogeneity and allowing for dynamic control of reactions to care and variations in genomics.According to Renub Research analysis, Global Liquid Biopsy Market is expected to be US$ 3.1 Billion by 2026.The major growth drivers of liquid biopsies are that while extracting the tissue sample from the human body is much pain-free, it substitutes the pain associated with the procedure.The COVID-19 effect in the liquid biopsy market has been harsh because all patients are taking therapies to treat cancer; since they have a weak immune system, and they are less prone to fight with coronavirus diseases.Renub Research report titled “Liquid Biopsy Market Global Forecast by Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others), Product (Kits & Consumables, Instruments and Services), Sample (Plasma/Serum, Urine & Others), Circulating Biomarkers (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening), Regions (Europe, North America, Latin America, Asia-Pacific and Middle East/Africa), Companies (Roche Diagnostics, Thermo Fisher Scientific Inc., Biocept Inc., Bio-Rad Laboratories Inc., Genomic Health, Biocartis, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories)” provides a detailed analysis of Global Liquid Biopsy Industry.Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=liquid-biopsy-market-p.phpBy Cancer1.We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting.We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
 To order this detailed 320+ page report, please visit this link Key InclusionsA detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any).A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography.Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity.An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.Elaborate profiles of key players that offer contract biomanufacturing services using microbial expression systems across different geographies, namely North America, Europe and Asia Pacific.Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field.It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.An insightful discussion on the impact of COVID-19 outbreak on the overall microbial contract biomanufacturing market, and the key initiatives undertaken by CMOs to combat the challenges posed due to ongoing situation.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Type of ProductAPIFDF Type of BiologicProteinsEnzymesGrowth HormonesAntibody based DrugsOthers (plasmid DNA, probiotics, microbiome-based biologics) Type of Microbial Expression SystemBacteriaYeastOthers (Algae and fungi) Scale of OperationCommercialPreclinical / Clinical Type of End UserSmall CompaniesMid-sized CompaniesLarge / Very Large Companies Key Geographical RegionsNorth AmericaEuropeAsia PacificMiddle East and North AfricaLatin America To request sample pages, please visit this link Key Questions AnsweredWho are the leading CMOs with expertise in production of microbial biologics?What are the preferred microbial expression systems used in biologic development and manufacturing?What are the key microbial fermentation technology platforms?Who could be the potential partners for the microbial CMOs?What kind of partnership models are commonly adopted by stakeholders engaged in this domain?What type of expansion initiatives are being carried out by CMOs in this domain?What initiatives are being undertaken by big pharma players in this domain?What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?What are the key trends within the microbial contract biomanufacturing market?How is the current and future market opportunity likely to be distributed across key market segments?You may also be interested in the following titles:Drug Repurposing Service Providers Market, 2020 – 2030Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030 Contact UsGaurav Chaudhary+1 (415) 800 [email protected]
 Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:Type of ProductAPIFDF Type of BiologicProteinsEnzymesGrowth HormonesAntibody based DrugsOthers (plasmid DNA, probiotics, microbiome-based biologics) Type of Microbial Expression SystemBacteriaYeastOthers (Algae and fungi) Scale of OperationCommercialPreclinical / Clinical Type of End UserSmall CompaniesMid-sized CompaniesLarge / Very Large Companies Key Geographical RegionsNorth AmericaEuropeAsia PacificMiddle East and North AfricaLatin America The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: AGC BiologicsAldevronBioVectraEirGenixEtinproEurogentecNorthway BiotechpharmaOlogy BioservicesPorton BiopharmaStelis Biopharma Table of Contents  Preface 2.Executive Summary Introduction Market Landscape Company Competitiveness Analysis  Company Profiles  Recent Partnerships Recent Expansions Microbial fermentation technology platforms Assessment of Relative Competition and Growth Make versus Buy Decision Making Framework  Big Pharma Initiatives in Microbial Biomanufacturing  Case study: comparison of small molecule and large   Market Sizing and Opportunity Analysis Impact of covid-19 pandemic on microbial contract biomanufacturing market  Swot Analysis   Conclusion Appendix 3: List of Companies and Organizations Interview Transcripts  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected] 
Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market.It features a detailed analysis of key drivers and trends related to this evolving domain.In addition to other elements, the study includes:A detailed review of the current landscape of companies offering contract manufacturing services.Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.An analysis of the partnerships and expansions that have been established in this domain, in the recent past.A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.A detailed proprietary 2×2 representation to assess the current market scenarioAn analysis of the initiatives of big biopharma players engaged in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Type of ProductAPIFDF Type of BiologicProteinsEnzymesGrowth HormonesAntibody based DrugsOthers (plasmid DNA, probiotics, microbiome-based biologics) Type of Microbial Expression SystemBacteriaYeastOthers (Algae and fungi) Scale of OperationCommercialPreclinical / Clinical Type of End UserSmall CompaniesMid-sized CompaniesLarge / Very Large Companies Key Geographical RegionsNorth AmericaEuropeAsia PacificMiddle East and North AfricaLatin America Transcripts of interviews held with the following senior level representatives of stakeholder companiesGaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)Max Rossetto (General Manager, Business Development, Luina Bio)Rob van Dijk (Business Development Manager, WACKER Biotech)  Key companies covered in the reportAGC BiologicsAldevronBioVectraEirGenixEtinproEurogentecNorthway BiotechpharmaOlogy BioservicesPorton BiopharmaStelis Biopharma For additional details, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email [email protected] You may also be interested in the following titles:Drug Repurposing Service Providers Market, 2020 – 2030Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030 Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 [email protected]
More

Top